相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation
Winson S. Ho et al.
CANCER LETTERS (2018)
Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial
Vincent Chung et al.
CLINICAL CANCER RESEARCH (2017)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter J. R. Ebert et al.
IMMUNITY (2016)
Ionic immune suppression within the tumour microenvironment limits T cell effector function
Robert Eil et al.
NATURE (2016)
PP2A's restraint of mTOR is critical for Treg cell activity
Greg M. Delgoffe
NATURE IMMUNOLOGY (2016)
Phosphatase PP2A is requisite for the function of regulatory T cells
Sokratis A. Apostolidis et al.
NATURE IMMUNOLOGY (2016)
Rescue of GABAB and GIRK function in the lateral habenula by protein phosphatase 2A inhibition ameliorates depression-like phenotypes in mice
Salvatore Lecca et al.
NATURE MEDICINE (2016)
LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential
Christopher S. Hong et al.
CANCER BIOLOGY & THERAPY (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Protein Phosphatase 2A Inhibition with LB100 Enhances Radiation-Induced Mitotic Catastrophe and Tumor Growth Delay in Glioblastoma
Ira K. Gordon et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Protein Phosphatase 2A Inhibitor LB100 Sensitizes Ovarian Carcinoma Cells to Cisplatin-Mediated Cytotoxicity
Ki-Eun Chang et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis
Xueli Bai et al.
CANCER LETTERS (2014)
mTOR signaling, Tregs and immune modulation
Nicole M. Chapman et al.
IMMUNOTHERAPY (2014)
Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas
Xue-Li Bai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
In vivo discovery of immunotherapy targets in the tumour microenvironment
Penghui Zhou et al.
NATURE (2014)
CANCER Live screening of immunotherapy targets
Katie Kingwell
NATURE REVIEWS DRUG DISCOVERY (2014)
T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
Ignacio Melero et al.
CANCER DISCOVERY (2014)
Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair
Dongping Wei et al.
CLINICAL CANCER RESEARCH (2013)
Viewing serine/threonine protein phosphatases through the eyes of drug designers
Mengmeng Zhang et al.
FEBS JOURNAL (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
V. Janssens et al.
CURRENT MOLECULAR MEDICINE (2012)
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
Greg M. Delgoffe et al.
NATURE IMMUNOLOGY (2011)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms
Jie Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
Sokol Haxhinasto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail)
Veerle Janssens et al.
TRENDS IN BIOCHEMICAL SCIENCES (2008)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Microcystin-LR and okadaic acid-induced cellular effects: a dualistic response
MM Gehringer
FEBS LETTERS (2004)
The toxic responses induced by okadaic acid involve processing of multiple caspase isoforms
GP Rossini et al.
TOXICON (2001)
Preliminary evidence for in vivo tumour initiation by oral administration of extracts of the blue-green alga Cylindrospermopsis raciborskii containing the toxin cylindrospermopsin
IR Falconer et al.
ENVIRONMENTAL TOXICOLOGY (2001)
分享论文
